JP2011504366A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011504366A5 JP2011504366A5 JP2010534544A JP2010534544A JP2011504366A5 JP 2011504366 A5 JP2011504366 A5 JP 2011504366A5 JP 2010534544 A JP2010534544 A JP 2010534544A JP 2010534544 A JP2010534544 A JP 2010534544A JP 2011504366 A5 JP2011504366 A5 JP 2011504366A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- cells
- clostridium difficile
- bacteriophage
- endolysin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims 50
- 229920001184 polypeptide Polymers 0.000 claims 38
- 102000004196 processed proteins & peptides Human genes 0.000 claims 38
- 108090000765 processed proteins & peptides Proteins 0.000 claims 38
- 241000193163 Clostridioides difficile Species 0.000 claims 25
- 241001515965 unidentified phage Species 0.000 claims 20
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 16
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims 15
- 230000000813 microbial effect Effects 0.000 claims 13
- 102000039446 nucleic acids Human genes 0.000 claims 13
- 108020004707 nucleic acids Proteins 0.000 claims 13
- 150000007523 nucleic acids Chemical class 0.000 claims 13
- 230000001580 bacterial effect Effects 0.000 claims 10
- 230000009089 cytolysis Effects 0.000 claims 10
- 230000001461 cytolytic effect Effects 0.000 claims 10
- 230000027455 binding Effects 0.000 claims 4
- 230000002934 lysing effect Effects 0.000 claims 4
- 150000001413 amino acids Chemical group 0.000 claims 3
- 210000002421 cell wall Anatomy 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 230000004927 fusion Effects 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 244000005700 microbiome Species 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 101710202200 Endolysin A Proteins 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 244000052616 bacterial pathogen Species 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99656307P | 2007-11-26 | 2007-11-26 | |
| PCT/GB2008/003923 WO2009068858A1 (en) | 2007-11-26 | 2008-11-24 | Novel polypeptides having endolysin activity and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011504366A JP2011504366A (ja) | 2011-02-10 |
| JP2011504366A5 true JP2011504366A5 (enExample) | 2012-01-12 |
Family
ID=40303496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010534544A Pending JP2011504366A (ja) | 2007-11-26 | 2008-11-24 | エンドリシン活性を有する新規ポリペプチド及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20100310522A1 (enExample) |
| EP (1) | EP2225263A1 (enExample) |
| JP (1) | JP2011504366A (enExample) |
| AU (1) | AU2008328584A1 (enExample) |
| CA (1) | CA2706600A1 (enExample) |
| WO (1) | WO2009068858A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0815484D0 (en) | 2008-08-26 | 2008-10-01 | Univ Leuven Kath | Antibacterial agents |
| GB0908949D0 (en) * | 2009-05-26 | 2009-07-01 | Plant Bioscience Ltd | Novel polypeptides having endolysin activity and uses thereof |
| EA037202B1 (ru) | 2009-06-26 | 2021-02-18 | Катхолике Университейт Лёвен, К.У. Лёвен Р Энд Д | Слитые белки для лечения инфекций, вызванных грамотрицательными бактериями |
| CN102482655B (zh) | 2009-06-26 | 2018-04-10 | 莱桑多公司 | 抗微生物剂 |
| MX383544B (es) | 2011-04-21 | 2025-03-14 | Univ Rockefeller | Lisinas de bacteriofago de streptococcus para la deteccion y tratamiento de bacterias gram positivas |
| KR101177358B1 (ko) | 2011-11-10 | 2012-08-27 | 서울대학교산학협력단 | 펩티다아제 활성이 있는 엔돌라이신 ＬｙｓＢ４, 이를 포함하는 식품 및 사료 조성물 |
| GB201215184D0 (en) | 2012-08-24 | 2012-10-10 | Univ Leicester | Therapeutic virus |
| US9493518B2 (en) * | 2013-03-14 | 2016-11-15 | National Health Research Institutes | Compositions and methods for treating clostridium difficile-associated diseases |
| US20180353575A1 (en) * | 2015-09-13 | 2018-12-13 | The Rockefeller University | Clostridium difficile bacteriophage lysins for detection and treatment of clostridium difficile bacteria infection |
| KR101880929B1 (ko) | 2016-06-30 | 2018-08-16 | 경희대학교 산학협력단 | 미생물 검출용 융합 단백질, 및 이의 제조방법 |
| EP3372091A1 (en) * | 2017-03-07 | 2018-09-12 | Nomad Bioscience GmbH | Method of reducing contamination of an object with clostridium |
| WO2020142306A2 (en) * | 2018-12-24 | 2020-07-09 | University Of South Florida | Engineered lysin-human defensin protein |
| CN120136980A (zh) * | 2019-05-08 | 2025-06-13 | 生物技术公司 | 新的加德纳菌内溶素及其用途 |
| WO2022182830A1 (en) * | 2021-02-25 | 2022-09-01 | Trustees Of Dartmouth College | Thermostable clostridium difficile lysins |
| AU2023304968A1 (en) * | 2022-07-05 | 2025-01-16 | Aushealth Corporate Pty Ltd | Method of production of modified phage and method of treatment using same |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1203333B (it) * | 1987-02-16 | 1989-02-15 | Endura Spa | Impiego di derivati del metilendiossibenzene con funzione sinergizzante in composizioni per uso insetticida |
| GB2255561B (en) * | 1991-04-20 | 1995-06-21 | Agricultural & Food Res | Lysins from bacteriophages |
| WO1995003035A1 (en) * | 1993-07-23 | 1995-02-02 | Massachusetts Institute Of Technology | Polymerized liposomes with enhanced stability for oral delivery |
| US6225290B1 (en) * | 1996-09-19 | 2001-05-01 | The Regents Of The University Of California | Systemic gene therapy by intestinal cell transformation |
| ID29150A (id) * | 1999-01-15 | 2001-08-02 | Entpr Ireland Cs | Penggunaan lactobacillus salivarius |
| GB0202556D0 (en) * | 2002-02-04 | 2002-03-20 | Danisco | Novel Protein |
| SE0201659D0 (sv) * | 2002-05-31 | 2002-05-31 | Astrazeneca Ab | Modified release pharmaceutical formulation |
-
2008
- 2008-11-24 CA CA2706600A patent/CA2706600A1/en not_active Abandoned
- 2008-11-24 EP EP08854675A patent/EP2225263A1/en not_active Withdrawn
- 2008-11-24 US US12/744,602 patent/US20100310522A1/en not_active Abandoned
- 2008-11-24 WO PCT/GB2008/003923 patent/WO2009068858A1/en not_active Ceased
- 2008-11-24 JP JP2010534544A patent/JP2011504366A/ja active Pending
- 2008-11-24 AU AU2008328584A patent/AU2008328584A1/en not_active Abandoned
-
2015
- 2015-03-27 US US14/671,319 patent/US20160045578A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011504366A5 (enExample) | ||
| US8066990B2 (en) | Lysin protein having broad antibacterial activity specific to bacteria | |
| Ji et al. | Preventive effect of the phage VB-SavM-JYL01 on rabbit necrotizing pneumonia caused by Staphylococcus aureus | |
| Van Pijkeren et al. | Genome editing of food-grade lactobacilli to develop therapeutic probiotics | |
| US12257284B2 (en) | Lantibiotics, lantibiotic-producing bacteria, compositions and methods of production and use thereof | |
| Brüggemann et al. | Bacteriophages infecting Propionibacterium acnes | |
| US10953052B2 (en) | Modifying bacteriophage | |
| US8377866B2 (en) | Antimicrobial protein derived from Podoviridae bacteriophage specific to Staphylococcus aureus | |
| Canfield et al. | Molecular mechanisms of enterococcal-bacteriophage interactions and implications for human health | |
| Liu et al. | Selection of potential virulence factors contributing to Streptococcus suis serotype 2 penetration into the blood-brain barrier in an in vitro co-culture model | |
| WO2016184274A1 (zh) | 一种葡萄球菌裂解酶及其应用 | |
| Lawrence et al. | A gut-derived Streptococcus salivarius produces the novel nisin variant designated nisin G and inhibits Fusobacterium nucleatum in a model of the human distal colon microbiome | |
| CN101780273A (zh) | 一种哈氏弧菌分泌型疫苗及其构建和应用 | |
| CN103911337B (zh) | 高粘附性丁酸梭菌及其制备方法 | |
| JP2017531432A (ja) | バクテリオファージの改変 | |
| CN110016457A (zh) | 一株重组细粒棘球蚴Eg95基因的粗糙型布鲁氏菌及其疫苗生产方法 | |
| ES2710931T3 (es) | Bacteriófagos terapéuticos | |
| WO2021079986A1 (ja) | バクテリオファージ組成物 | |
| García et al. | Pneumococcal phages | |
| EP4135733A2 (en) | Engineered probiotics for treatment and immunity against viruses | |
| WO2021079536A1 (ja) | バクテリオファージ組成物 | |
| Wong et al. | Escherichia coli BarA-UvrY regulates the pks island and kills Staphylococci via the genotoxin colibactin | |
| Jedariforoughi | BACTERIOPHAGE | |
| Jedariforoughi | A book about bacteriophage | |
| JP7385233B2 (ja) | 黄色ブドウ球菌および／または緑膿菌を原因とする感染症の治療剤 |